pak 104p has been researched along with etoposide in 1 studies
Studies (pak 104p) | Trials (pak 104p) | Recent Studies (post-2010) (pak 104p) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
---|---|---|---|---|---|
16 | 0 | 0 | 18,306 | 3,693 | 4,900 |
Protein | Taxonomy | pak 104p (IC50) | etoposide (IC50) |
---|---|---|---|
nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
Caspase-3 | Homo sapiens (human) | 1 | |
DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aikou, T; Akiyama, S; Furukawa, T; Ikeda, R; Kitazono, M; Nagayama, S; Okumura, H; Seto, K; Sumizawa, T | 1 |
1 other study(ies) available for pak 104p and etoposide
Article | Year |
---|---|
Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzylisoquinolines; Butyrates; Carcinoma; Cell Nucleus; Colonic Neoplasms; Coloring Agents; Cyclic P-Oxides; Cytoplasm; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Microscopy, Fluorescence; Neoplasm Proteins; Nicotinic Acids; RNA, Catalytic; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2001 |